Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Mycosis Fungoides 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Waldenstrom Macroglobulinemia 1Neoplasms 1Neoplasm Metastasis 1Mycoses 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

pembrolizumab 12Cisplatin 5Cetuximab 5Paclitaxel 4durvalumab 3Nivolumab 3Ipilimumab 3Gemcitabine 3Cyclophosphamide 3poly ICLC 2avelumab 2Radiation 2Pemetrexed 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tislelizumab 1tirbanibulin 1spartalizumab 1sonidegib 1sitravatinib 1repotrectinib 1pralsetinib 1pertuzumab 1pepinemab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma × ProMune × Clear all
NCT00031278 2011-05-30

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡